Meta-analyses have also shown that SGLT2 inhibitors can reduce hepatic enzymes (e.g., ALT and AST), hepatic fat contents, and Fibrosis-4 (FIB-4) levels, suggesting they alleviate MASLD and its progression to MASH [106]. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.